Sources: Healthline
SGLT2i, sodium-glucose cotransporter-2 inhibitor
It changes by phase: the documented schedule begins at 0.25 mg/week and climbs, roughly monthly, toward the 2.4 mg/week maintenance dose
This guide explores the biology behind GLP-1 facial fat loss and highlights how skincare, lifestyle habits, and non-invasive treatments such as ultrasound collagen remodeling can support the appearance of facial wrinkles
What this means for you: Don't judge a dose's effectiveness until you've been on it for at least 4 weeks
In the SURPASS-4 trial, adults with T2DM at heightened cardiovascular risk, who were inadequately managed with oral glucose-lowering agents, once-weekly tirzepatide (5 mg, 10 mg, or 15 mg) were compared to insulin glargine (100 U/mL)